Copyright © Inderes 2011 - present. All rights reserved.

Bioretec

0.46 EUR

-2.78 %

1,713 following
Corporate customer

BRETEC

First North Finland

Medical Equipment & Services

Health Care

-2.78 %
-24.17 %
-22.88 %
-67.62 %
-75.07 %
-79.35 %
-77.91 %
-
-83.85 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
14.01M EUR
Turnover
36.55K EUR
P/E (adj.) (25e)
-1.49
EV/EBIT (adj.) (25e)
-1.15
P/B (25e)
1.49
EV/S (25e)
2.54
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
0.60 EUR
Updated
16.12.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 17.12.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.2
2026

Annual report '25

8.5
2026

General meeting '26

14.5
2026

Business review Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Something positive for a change. Bioretec has been granted U.S. Food and Drug Administration (FDA) Breakthrough Device Designation status. Time will tell if that turns into money at some point. Bioretec Tiedotteet | Bioretec Bioretec on suomalainen, globaalisti toimiva lääkinnällisi...
12/14/2025, 5:14 PM
by makuasia
23
Financial Goals: In line with the strategy and the priorities for the 2026-2028 period, Bioretec’s new financial goals are: Achieve a turnover of over 10 million euros by the end of 2028 Maintain an average sales margin of over 70% throughout the strategy period A new three-year ...
12/16/2025, 7:17 AM
by Umpi
13
Antti discussed Bioretec’s new strategy and financial goals with Bioretec CEO Sarah Hubar-Fisher. Inderes Bioretec: Tavoitteita laskettiin (eng.) - Inderes Aika: 18.12.2025 klo 17.39 Bioretec päivitti strategiansa ja taloudelliset tavoitteet vuosille 2026–28. Yhtiö leikkasi vuoden...
12/18/2025, 4:54 PM
by Sijoittaja-alokas
12
I think tax-loss selling is a rather poor explanation for the recent decline, as the reasons lie more in the company’s performance. The final push for the drop was the updated strategy, and any remaining faith for some shareholders vanished following Siltanen’s recommendation change...
12/22/2025, 2:36 PM
10
Here are Antti’s comments regarding this latest release. Bioretec announced on Sunday that the U.S. Food and Drug Administration (FDA) has granted its RemeOs-DrillPin Breakthrough Device Designation status. The news is a positive indication of the company’s technology potential and...
12/15/2025, 6:26 AM
by Sijoittaja-alokas
9
Antti has written a new company report on Bioretec, following these companies’ new “updates”. Bioretec updated its strategy and financial targets for 2026–28. The company cut its 2028 revenue target to 10 MEUR (prev. 65 MEUR). The turnaround in earnings has also moved further away...
12/17/2025, 5:43 AM
by Sijoittaja-alokas
8
Now during the tax-loss selling season, the share price has been driven into the ground and I’ve just been loading up on more… My own position is also heavily in the red, but I believe the products are so superior compared to competing products that a positive turnaround is bound...
12/22/2025, 10:13 AM
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.